Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Treatments & Surgery
Share your love
Chronic nAMD With Cataract Complications: Visual Stabilization Through Sequential Anti-VEGF Strategies | Ophthalmology Times
Treatment-Resistant Retinal Disease Management With Sequential Anti-VEGF Strategies This comprehensive presentation examines complex retinal disease management using sequential anti-VEGF therapies, supported by pharmacokinetic modeling from 17 aflibercept trials involving 2700 individuals. The data demonstrates that aflibercept 8 mg exhibits 34.4%…
Lupin signs definitive agreement to acquire VISUfarma | Ophthalmology Times
(Image Credit: AdobeStock/Rido) Lupin’s subsidiary, Nanomi, has signed a definitive agreement to acquire VISUfarma, a portfolio company of GHO Capital Partners LLP. Lupin notes that the acquisition will help the company expand its European business, as well as advance the…
Q&A: Alexandra Miere discusses the ACTOR and HERMES studies | Ophthalmology Times
Photo of Alexandra Miere at the 2025 EURETINA meeting in Paris Alexandra Miere discusses retinal studies published in EURETINA journal. The first, the ACTOR study, explores vascular remodeling in neovascular AMD patients treated with ranibizumab. The second, the HERMES study,…
Anniversary of the spectral OCT prototype: 25 years young and growing | Ophthalmology Times
A recent conference celebrated the creation of the first prototype of the spectral optical coherence tomography (SOCT) instrument. Introduced in 2000, the prototype, which was developed at the Institute of Physics of Nicolaus Copernicus University in Toruń, Poland, was the…
The Netherlands: Lupin strengthens ophthalmology business with acquisition of VISUfarma from GHO Capital
\n European specialist investor GHO Capital Partners has announced the sale of its portfolio company, VISUfarma, a Netherlands-headquartered specialty pharmaceutical company focused on ophthalmology, to global pharma major Lupin. \n\n\n\n VISUfarma was created by GHO Capital in 2016 by combining…
EyeCon 2025: Adopting an interventional glaucoma mindset with Oluwatosin U. Smith, MD | Ophthalmology Times
At this year’s EyeCon meeting, Oluwatosin U. Smith, MD, of the Glaucoma Associates of Texas, reflected on her dual role—both as an educator and a leader in its development—while delivering a focused presentation on the current state of glaucoma care.…
Looking ahead: Ophthalmologists envision a world without the toughest diseases | Ophthalmology Times
As Ophthalmology Times celebrates its 50th anniversary, we took the opportunity to ask a thought-provoking question to some of the field’s leading experts: “In a perfect world, if you could cure one eye disease or condition with the snap of…
Q&A: Boris Stanzel on the use of methotrexate in PVR cases | Ophthalmology Times
Photo of Boris Stanzel, MD, at the 2025 EURETINA meeting Professor Boris Stanzel, MD, presented research on methotrexate’s use in PVR retinal detachment surgery at the 2025 EURETINA congress, which was held in Paris, France. The study of 20 patients…
Increased complications in cataract surgery during the COVID-19 pandemic | Ophthalmology Times
(Image credit: AdobeStock/phonlamaiphoto) Canadian researchers recently reported significant increases in complications during cataract surgeries performed during the COVID-19 pandemic compared with the pre-pandemic period.1 First author Nathan Lee-Wing, BS, and MD candidate at the Max Rady College of Medicine, University…
FDA approves abbreviated new drug application from Amneal Pharmaceuticals for bimatoprost ophthalmic solution 0.01% | Ophthalmology Times
(Image Credit: AdobeStock) The US Food and Drug Administration (FDA) has approved Amneal Pharmaceuticals’ Abbreviated New Drug Application (ANDA) for bimatoprost ophthalmic solution 0.01% (2.5 mL, 5 mL and 7.5 mL).1 An ANDA is a submission to the FDA that…